Coverage of our peer-reviewed research in the healthcare and mainstream press.
In a column for Massachusetts news outlet Melrose Free Press, State Senator Jason Lewis outlined the promises of telemedicine and his goal to pass legislation that would expand access to telehealth services. He cited a 2015 study published in The American Journal of Managed Care® (AJMC®), “Opportunity Costs of Ambulatory Medical Care in the United States,” which found that although medical visits take up an average 2 hours of a patient’s time, only 20 minutes are actually spent face-to-face with a physician. Lewis argued that telemedicine visits can eliminate the time spent traveling to clinics and ideally provide more convenient and accessible care.
A press release from insurer Anthem described its survey published in Benefits Quarterly, which found that 90% of large employers considered the cost of new specialty drugs a challenge. To explain this burden, it referenced a Payer Perspective article titled “The Growing Cost of Specialty Pharmacy: Is it Sustainable?” and published by AJMC® in 2013. This article discussed how the array of specialty drugs on the market had “grown substantially” from 10 in 1990 to nearly 300 in 2012.
There are 3 significant challenges providers face in implementing payments, according to an article on RevCycleIntelligence.com, including the unexpected spending that can arise as a result of complications or nonadherence. It illustrated this point with a quote from a 2016 AJMC® interview, “Dr Joshua Cohen Considers the Cons of Bundled Payments.” “There are situations where using a bundle may be inappropriate because the factors that are influencing differences in cost among patients are things that the provider doesn’t actually control,” Cohen said.
Global Trends in Ovarian Cancer Incidence Highlight Regional, Histological Variations
January 7th 2025Between 1988 and 2017, there were significant global variations and trends in ovarian cancer incidence and its subtypes, influenced by genetic, reproductive, and socioeconomic factors.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More